Novo Nordisk is investing $409 million in a new state-of-the-art quality control laboratory in Hillerød, Denmark. The new facility, covering 53,000 square meters, will be the company’s largest investment in advanced quality control to date. 
 
The new lab will serve as a central hub for quality control operations in Denmark, consolidating existing locations into a world-class facility. It is designed to comply with the demands of current and future Good Manufacturing Practice (GMP) and will support demand as well as provide the flexibility to support future capacity expansions. The facility will use new technologies and digitalization to automate processes to help further strengthen quality control processes.
 
“This state-of-the-art quality control laboratory highlights Novo Nordisk’s global growth journey and our dedication to innovation, says Erik Lorin Rasmussen, senior vice president of Product Supply, Aseptic Manufacturing. “As we expand our manufacturing capacity and anticipate new products to meet the growing global demand, this new quality control facility will play an important role in ensuring the quality of our products and position us to meet the evolving requirements of patients and regulators.”
 
Construction has been initiated and will be finalized in 2027.